Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 162,000 shares, a growth of 74.8% from the March 15th total of 92,700 shares. Based on an average daily trading volume, of 241,700 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SLN shares. HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. BMO Capital Markets started coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They set an "outperform" rating and a $67.00 price objective on the stock. Morgan Stanley increased their price objective on Silence Therapeutics from $29.00 to $45.00 and gave the stock an "overweight" rating in a research report on Thursday, March 14th. Finally, Chardan Capital raised their price target on Silence Therapeutics from $26.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, March 14th.

Silence Therapeutics Price Performance

NASDAQ:SLN traded down $0.19 during trading hours on Friday, hitting $22.17. The company's stock had a trading volume of 104,272 shares, compared to its average volume of 243,680. The stock has a fifty day simple moving average of $23.00 and a 200-day simple moving average of $16.63. The company has a market capitalization of $663.55 million, a P/E ratio of -15.18 and a beta of 1.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.56. Silence Therapeutics has a twelve month low of $4.55 and a twelve month high of $27.72.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.22). The business had revenue of $2.61 million during the quarter, compared to analyst estimates of $11.46 million. Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. On average, analysts anticipate that Silence Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently made changes to their positions in SLN. Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics during the fourth quarter valued at about $8,862,000. Lynx1 Capital Management LP acquired a new stake in shares of Silence Therapeutics during the third quarter valued at about $2,315,000. Goldman Sachs Group Inc. boosted its stake in shares of Silence Therapeutics by 27.1% during the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock valued at $18,350,000 after purchasing an additional 205,815 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Silence Therapeutics by 66.6% during the second quarter. Woodline Partners LP now owns 239,360 shares of the company's stock valued at $1,316,000 after purchasing an additional 95,676 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of Silence Therapeutics by 36.0% during the fourth quarter. Morgan Stanley now owns 210,973 shares of the company's stock valued at $3,217,000 after purchasing an additional 55,814 shares in the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.